Phosphoramidon

Summary

Phosphoramidon is a research‑grade pseudo‑peptide metalloprotease inhibitor, classified among phosphoramidon‑type compounds. It blocks several zinc‑dependent endopeptidases, notably neprilysin‑like enzymes, endothelin‑converting enzyme (ECE) and endopeptidase‑24.11. In laboratory studies it is used to probe the roles of these enzymes in amyloid‑beta clearance, endothelin production, and opioid peptide metabolism, and to model disease mechanisms in Alzheimer’s disease, Chagas‑related cardiomyopathy, and neuropeptide signaling.

Mechanism of Action

Phosphoramidon binds to the active‑site zinc ion of metalloproteases, preventing substrate hydrolysis. It potently inhibits neprilysin‑like endopeptidases (including neprilysin and NEP‑2) that degrade amyloid‑beta, as well as endothelin‑converting enzyme‑1, which processes big‑endothelin to active endothelin‑1. It also blocks endopeptidase‑24.11, an enzyme that rapidly cleaves enkephalins near opioid receptors. By halting these cleavage reactions, phosphoramidon raises levels of the native peptides and alters downstream signaling pathways.

What the Research Shows

Animal and in‑vitro work shows that phosphoramidon dramatically raises brain amyloid‑beta when administered to rodents, supporting a key role for NEP‑like enzymes in peptide clearance (Marr & Spencer, 2010; Marr & Hafez, 2014). In a mouse model of Trypanosoma cruzi infection, phosphoramidon inhibition of endothelin‑converting enzyme reduced heart enlargement and pathology, linking endothelin production to chagasic cardiomyopathy (Petkova et al., 2001). Early biochemical studies identified phosphoramidon as a selective inhibitor of the metalloprotease form of ECE, distinguishing it from other E‑24.11 inhibitors (Opgenorth et al., 1992; Turner & Murphy, 1996). In guinea‑pig and rodent tissue preparations, phosphoramidon enhanced the contractile effects of enkephalins by preventing their rapid degradation, indicating proximity of the inhibited endopeptidase to opioid receptors (Oka et al., 1993). Across these studies, phosphoramidon is employed primarily as a tool to dissect enzyme function rather than as a therapeutic agent.

Reported Benefits

The compound provides a valuable experimental probe for delineating the contribution of metalloproteases to peptide homeostasis. It has clarified that neprilysin‑like enzymes regulate amyloid‑beta levels, that endothelin‑converting enzyme drives endothelin‑1 production in cardiac disease models, and that endopeptidase‑24.11 modulates opioid peptide activity. These insights have guided the development of more selective inhibitors and gene‑therapy concepts aimed at enhancing peptide clearance or reducing pathogenic peptide generation.

Limitations of the Evidence

Evidence is confined to animal models and cell‑based assays; no human clinical data exist. Phosphoramidon lacks specificity, inhibiting multiple metalloproteases, which can confound interpretation of results. The increase in amyloid‑beta observed after inhibition raises concerns about potential adverse effects if translated to therapy. Moreover, the long‑term consequences of endothelin suppression in vivo remain untested, and the compound’s pharmacokinetic properties are not described in the literature.

Safety Considerations

Safety information is limited to preclinical use. No adverse events are reported in the cited abstracts, but inhibition of neprilysin‑like enzymes can elevate amyloid‑beta, and blockade of endothelin conversion may alter vascular tone. Consequently, extrapolation to human use is cautioned. Researchers should handle phosphoramidon according to standard laboratory safety protocols for bioactive chemicals and monitor animal subjects for unexpected physiological changes.

How It Is Administered

Phosphoramidon has been applied in vitro to enzyme preparations and tissue extracts, and administered intravenously in rodent studies of amyloid‑beta and endothelin biology. Formulations are not detailed in the abstracts; the compound is typically supplied as a salt (e.g., disodium) for dissolution in aqueous buffers before use.

Routes of Administration

Goals & Uses

• Inhibition of endothelin-converting enzyme (ECE)Research / Pharmacological ToolHigh
• Inhibition of neprilysin (NEP) activityResearch / Pharmacological ToolHigh
• Study of enkephalin and atrial natriuretic peptide metabolismNeuropharmacology / Cardiovascular ResearchModerate
• Characterization of thermolysin activityBiochemical ResearchHigh

Contraindications

• Human therapeutic administrationClinical UseHigh

Adverse Effects

• Broad metalloprotease inhibitionOff Target EffectsUnknown
• Cardiovascular effects (in vivo animal studies)CardiovascularUnknown

Drug Interactions

• Neprilysin substrates (ANP, BNP, enkephalins)Low
• Endothelin receptor antagonistsLow

Population Constraints

• Human useGeneral PopulationAbsolute

Regulatory Status

• European UnionUnapprovedResearch use only; no EMA authorization.
• United StatesUnapprovedResearch tool compound only; not an FDA-regulated drug for human use.
• United KingdomUnapprovedResearch use only; no MHRA authorization.

Not approved by any regulatory authority (FDA, EMA, MHRA) for human therapeutic use. Used exclusively as a research/tool compound in laboratory settings.

Evidence & Sources

• NEP-like endopeptidases and Alzheimer's disease [corrected]
  Journal ArticleModerateMarr RA, Spencer BJ2010-01-01T00:00:00.000000Z
• The role of endothelin in the pathogenesis of Chagas' disease
  Journal ArticleModeratePetkova SB, et al.2001-01-01T00:00:00.000000Z
• Endothelin-converting enzymes
  Journal ArticleModerateOpgenorth TJ, Wu-Wong JR, Shiosaki K1992-01-01T00:00:00.000000Z
• Amyloid-beta and Alzheimer's disease: the role of neprilysin-2 in amyloid-beta clearance
  Journal ArticleModerateMarr RA, Hafez DM2014-01-01T00:00:00.000000Z
• [Enkephalin-inactivating enzymes]
  Journal ArticleModerateOka T, et al.1993-01-01T00:00:00.000000Z
• Molecular pharmacology of endothelin converting enzymes
  Journal ArticleModerateTurner AJ, Murphy LJ1996-01-01T00:00:00.000000Z

Frequently Asked Questions